Next-generation biomarker discovery in Alzheimer’s disease using metabolomics–from animal to human studies

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · see citing works

Metabolomics—the link between genotypes and phenotypes

Fiehn, O. (2002) · Plant Molecular Biology · doi:10.1023/a:1013713905833 · Cited by 3,445 · see citing works

Metabolomics — the link between genotypes and phenotypes

Fiehn, O. (2002) · Springer eBooks · doi:10.1007/978-94-010-0448-0_11 · Cited by 3,168 · see citing works

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works

Untitled work

Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · see citing works

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease

Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185 · see citing works

Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease

Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,833 · see citing works

Emerging applications of metabolomics in drug discovery and precision medicine

Wishart, D. S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.32 · Cited by 1,499 · see citing works

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy

Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · see citing works

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · see citing works

Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease

Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K. J., Troncoso, J. C., & Mattson, M. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305799101 · Cited by 1,135 · see citing works

Neuropathology of Alzheimer's Disease

Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825 · see citing works

Alzheimer’s disease hypothesis and related therapies

Du, X., Wang, X., & Geng, M. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0107-y · Cited by 604 · see citing works

Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications

Mufson, E. J., Counts, S., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 589 · see citing works

Progression of Mild Cognitive Impairment to Dementia in Clinic- vs Community-Based Cohorts

Farias, S. T., Mungas, D., Reed, B., Harvey, D. J., & DeCarli, C. S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.106 · Cited by 582 · see citing works

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · see citing works

Identifying and validating biomarkers for Alzheimer's disease

Humpel, C. (2011) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.09.007 · Cited by 484 · see citing works

Advances in the early detection of Alzheimer's disease

Nestor, P. J., Scheltens, P., & Hodges, J. R. (2004) · Nature Medicine · doi:10.1038/nrn1433 · Cited by 465 · see citing works

Metabolic network failures in Alzheimer's disease: A biochemical road map

Toledo, J. B., Arnold, M., Kastenmüller, G., Chang, R. R., Baillie, R., Han, X., Thambisetty, M., Tenenbaum, J. D., Suhre, K., Thompson, J. W., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.020 · Cited by 454 · see citing works

Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics

Trushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M., & Petersen, R. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063644 · Cited by 438 · see citing works

Tau and Aβ42 in Cerebrospinal Fluid from Healthy Adults 21–93 Years of Age: Establishment of Reference Values

Sjögren, M., Vanderstichele, H., Ågren, H., Zachrisson, O., Edsbagge, M., Wikkelsø, C., Skoog, I., Wallin, A., Wahlund, L.-O., Marcusson, J., et al. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.10.1776 · Cited by 436 · see citing works

Metabolomics in Early Alzheimer's Disease: Identification of Altered Plasma Sphingolipidome Using Shotgun Lipidomics

Han, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429 · see citing works

Rate of Conversion from Prodromal Alzheimer's Disease to Alzheimer's Dementia: A Systematic Review of the Literature

Ward, A., Tardiff, S., Dye, C., & Arrighi, H. M. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000354370 · Cited by 426 · see citing works

Total and phosphorylated tau protein as biological markers of Alzheimer’s disease

Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · see citing works

Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease

Whiley, L., Sen, A., Heaton, J. C., Proitsi, P., García‐Gómez, D., Leung, R., Smith, N. W., Thambisetty, M., Kłoszewska, I., Mecocci, P., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.001 · Cited by 342 · see citing works

Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.130518 · Cited by 332 · see citing works

Brain Membrane Phospholipid Alterations in Alzheimer's Disease

Pettegrew, J. W., Panchalingam, K., Hamilton, R. L., & McClure, R. J. (2001) · Neurochemical Research · doi:10.1023/a:1011603916962 · Cited by 292 · see citing works

Plasma and Brain Fatty Acid Profiles in Mild Cognitive Impairment and Alzheimer's Disease

Cunnane, S. C., Schneider, J. A., Tangney, C., Tremblay‐Mercier, J., Fortier, M., Bennett, D. A. A., & Morris, M. C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-110629 · Cited by 288 · see citing works

Metabolome in progression to Alzheimer's disease

Orešič, M., Hyötyläinen, T., Herukka, S.-K., Sysi‐Aho, M., Mattila, I. M., Seppänan-Laakso, T., Julkunen, V., Gopalacharyulu, P. V., Hallikainen, M., Koikkalainen, J. R., et al. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.55 · Cited by 280 · see citing works

Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease

Mecocci, P., & Polidori, M. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.006 · Cited by 270 · see citing works

Lipid Alterations in Lipid Rafts from Alzheimer's Disease Human Brain Cortex

Martín, M. V., Fabelo, N., Santpere, G., Puig, B., Marín, R., Ferrer, I., & Díaz, M. L. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1242 · Cited by 269 · see citing works

Defects in Mitochondrial Dynamics and Metabolomic Signatures of Evolving Energetic Stress in Mouse Models of Familial Alzheimer's Disease

Trushina, E. V., Nemutlu, E., Zhang, S., Christensen, T. A., Camp, J. J., Mesa, J., Siddiqui, A., Tamura, Y., Sesaki, H., Wengenack, T. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032737 · Cited by 268 · see citing works

Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion

Schrag, M., Mueller, C., Oyoyo, U. E., Smith, M. A., & Kirsch, W. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.001 · Cited by 266 · see citing works

Free amino acid and dipeptide changes in the body fluids from Alzheimer’s disease subjects

Fonteh, A. N., Harrington, R. J., Tsai, A., Liao, P. S., & Harrington, M. G. (2006) · Amino Acids · doi:10.1007/s00726-006-0409-8 · Cited by 248 · see citing works

Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease

Cruchaga, C., Kauwe, J. S. K., Nowotny, P., Bales, K., Pickering, E. H., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A. M., Holtzman, D. M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds296 · Cited by 207 · see citing works

Alterations in metabolic pathways and networks in Alzheimer’s disease

Kaddurah‐Daouk, R., Zhu, H., Sharma, S., Bogdanov, M. B., Rozen, S., Matson, W. R., Oki, N. O., Motsinger‐Reif, A. A., Churchill, E., Lei, Z., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.18 · Cited by 205 · see citing works

Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis

Proitsi, P., Kim, M. G., Whiley, L., Simmons, A., Sattlecker, M., Velayudhan, L., Lupton, M. K., Soininen, H., Kłoszewska, I., Mecocci, P., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.003 · Cited by 203 · see citing works

Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy

Marjańska, M., Curran, G. L., Wengenack, T. M., Henry, P., Bliss, R., Poduslo, J. F., Jack, C. R., Uǧurbil, K., & Garwood, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505513102 · Cited by 198 · see citing works

Circulating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies

van der Lee, S. J., Teunissen, C. E., Pool, R., Shipley, M. J., Teumer, A., Chouraki, V., Melo van Lent, D., Tynkkynen, J., Fischer, K., Hernesniemi, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.012 · Cited by 197 · see citing works

Recent advances in the application of metabolomics to Alzheimer's Disease

Trushina, E. V., & Mielke, M. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.014 · Cited by 195 · see citing works

Altered arginine metabolism in Alzheimer's disease brains

Liu, P., Fleete, M. S., Yu, J., Collie, N. D., Curtis, M. A., Waldvogel, H. J., Faull, R. L. M., Abraham, W. C., & Zhang, H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.013 · Cited by 186 · see citing works

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C. M., Sokolow, S., Deyn, P. P. D., Galasko, D. R., Hampel, H. J., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 169 · see citing works

Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid

Czech, C., Berndt, P., Busch, K., Schmitz, O., Wiemer, J. C., Most, V., Hampel, H. J., Kastler, J., & Senn, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031501 · Cited by 167 · see citing works

Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid

Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & Bruijn, C. D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 167 · see citing works

Direct-injection mass spectrometry adds the time dimension to (B)VOC analysis

Biasioli, F., Yeretzian, C., Märk, T. D., et al. (2011) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2011.04.005 · Cited by 167 · see citing works

Toward a Predictive Model of Alzheimer’s Disease Progression Using Capillary Electrophoresis–Mass Spectrometry Metabolomics

Ibáñez, C., Simó, C., Martín‐Álvarez, P. J., Kivipelto, M., Winblad, B. G., Cedazo-Mı́nguez, Á., & Cifuentes, A. (2012) · Analytical Chemistry · doi:10.1021/ac301243k · Cited by 166 · see citing works

Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals

Casanova, R., Varma, S., Simpson, B. N., Kim, M. G., An, Y., Saldana, S. J., Riveros, C., Moscato, P., Griswold, M. E., Sonntag, D., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.12.008 · Cited by 162 · see citing works

Deregulation of purine metabolism in Alzheimer's disease

Ansoleaga, B., Jové, M., Schlüter, A., Garcia‐Esparcia, P., Moreno, J. R., Pujol, A., Pamplona, R., Portero‐Otín, M., & Ferrer, I. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.004 · Cited by 160 · see citing works

Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile

Dedeoglu, A., Choi, J., Cormier, K., Kowall, N. W., & Jenkins, B. G. (2004) · Brain Research · doi:10.1016/j.brainres.2004.02.079 · Cited by 158 · see citing works

Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology

Sato, Y., Suzuki, I., Nakamura, T., Bernier, F., Aoshima, K., & Oda, Y. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m022376 · Cited by 158 · see citing works

Plasma levels of apolipoprotein <scp>E</scp> and risk of dementia in the general population

Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156 · see citing works

Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers

Yassine, H. N., Braskie, M. N., Mack, W. J., Castor, K., Fonteh, A. N., Schneider, L. S. S., Harrington, M. G., & Chui, H. C. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4899 · Cited by 155 · see citing works

Tau Protein in Normal and Alzheimer's Disease Brain: An Update

Johnson, G. V. W., & Hartigan, J. A. (1999) · Journal of Alzheimer s Disease · doi:10.3233/jad-1999-14-512 · Cited by 154 · see citing works

Amyloid β protein in plasma from patients with sporadic Alzheimer's disease

Tamaoka, A., Fukushima, T., Sawamura, N., Ishikawa, K., Oguni, E., Komatsuzaki, Y., & Shoji, S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00143-8 · Cited by 154 · see citing works

Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer’s Disease

Pan, X., Elliott, C. T., McGuinness, B., Passmore, P., Kehoe, P. G., Hölscher, C., McClean, P. L., Graham, S. F., & Green, B. D. (2017) · Metabolites · doi:10.3390/metabo7020028 · Cited by 153 · see citing works

CSF biomarkers for mild cognitive impairment

Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works

Metabolic profiling of Alzheimer's disease brains

Inoue, K., Tsutsui, H., Akatsu, H., Hashizume, Y., Matsukawa, N., Yamamoto, T., & Toyo’oka, T. (2013) · Scientific Reports · doi:10.1038/srep02364 · Cited by 150 · see citing works

Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging

Gupta, V. B., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., Lui, J. K., Masters, C., Rowe, C. C., Szoeke, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318211c352 · Cited by 149 · see citing works

A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease

Salek, R. M., Xia, J., Innes, A. E., Sweatman, B. C., Adalbert, R., Randle, S. J., McGowan, E. M., Emson, P. C., & Griffin, J. L. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.04.001 · Cited by 146 · see citing works

Elevated stearoyl-CoA desaturase in brains of patients with Alzheimer’s disease

Astarita, G., Jung, K.-M., Vasilevko, V., DiPatrizio, N. V., Martin, S. K., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024777 · Cited by 146 · see citing works

The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin

Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.007 · Cited by 145 · see citing works

Metabolomic changes in autopsy‐confirmed Alzheimer's disease

Kaddurah-Daouk, R. F., Rozen, S., Matson, W. R., Han, X., Hulette, C. M., Burke, J. R., Doraiswamy, P. M., & Welsh-Bohmer, K. A. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.001 · Cited by 145 · see citing works

Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease

González‐Domínguez, R., García‐Barrera, T., & Gómez‐Ariza, J. L. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.01.014 · Cited by 144 · see citing works

ole of apoE/Aβ Interactions in the Pathogenesis of Alzheimer's Disease and Cerebral Amyloid Angiopathy

Holtzman, D. M. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:147 · Cited by 143 · see citing works

Two Distal Downstream Enhancers Direct Expression of the Human Apolipoprotein E Gene to Astrocytes in the Brain

Grehan, S., Tse, E., & Taylor, J. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00812.2001 · Cited by 138 · see citing works

Unbiased Metabolomic Investigation of Alzheimer’s Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism

Paglia, G., Stocchero, M., Cacciatore, S., Lai, S., Angel, P. M., Alam, M. T., Keller, M. A., Ralser, M., & Astarita, G. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01020 · Cited by 136 · see citing works

Next-generation capillary electrophoresis–mass spectrometry approaches in metabolomics

Zhang, W., Hankemeier, T., & Ramautar, R. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.07.002 · Cited by 129 · see citing works

Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset

Dionísio, P. A., Amaral, J. D., Ribeiro, M. F., Lo, A. C., D'Hooge, R., & Rodrigues, C. M. P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.034 · Cited by 127 · see citing works

Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

Hye, A., Kerr, F., Archer, N. J., Foy, C., Poppe, M., Brown, R. G., Hamilton, G., Powell, J. F., Anderton, B. H., & Lovestone, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.031 · Cited by 125 · see citing works

Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry

Li, N., Liu, W., Li, W., Li, S., Chen, X.-H., Bi, K., & He, P. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.04.072 · Cited by 125 · see citing works

Behavioral and Psychological Symptoms in Alzheimer’s Disease

Li, X., Hu, N., Tan, M., Yu, J., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/927804 · Cited by 124 · see citing works

Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study

Chouraki, V. A., Preis, S. R., Yang, Q., Beiser, A., Li, S., Larson, M. G., Weinstein, G., Wang, T. J., Gerszten, R. E., Vasan, R. S., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.04.009 · Cited by 122 · see citing works

Characterization of metal profiles in serum during the progression of Alzheimer's disease

González‐Domínguez, R., García‐Barrera, T., & Gómez‐Ariza, J. L. (2013) · Metallomics · doi:10.1039/c3mt00301a · Cited by 117 · see citing works

Amyloid β and APP as biomarkers for Alzheimer’s disease

Zetterberg, H., Blennow, K., & Hanse, E. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.08.002 · Cited by 113 · see citing works

APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease

Vélez, J. I., Lopera, F., Sepulveda-Falla, D., Patel, H. R., Johar, A. S., Chuah, A., Tobón, C., Rivera, D., Villegas, A., Cai, Y., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.177 · Cited by 111 · see citing works

A multi-metabolite analysis of serum by 1H NMR spectroscopy: Early systemic signs of Alzheimer’s disease

Tukiainen, T., Tynkkynen, T., Mäkinen, V., Jylänki, P., Kangas, A. J., Hokkanen, J., Vehtari, A., Gröhn, O. H. J., Hallikainen, M., Soininen, H. S., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.007 · Cited by 111 · see citing works

The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment

Klavins, K., Koal, T., Dallmann, G., Marksteiner, J., Kemmler, G., & Humpel, C. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.05.003 · Cited by 110 · see citing works

Alzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid

Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 109 · see citing works

Biomarkers in Sporadic and Familial Alzheimer’s Disease

Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106 · see citing works

Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span

von Kienlin, M., Künnecke, B., Metzger, F., Steiner, G., Richards, J. G., Ozmen, L., Jacobsen, H., & Loetscher, H. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.005 · Cited by 103 · see citing works

Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers

Roche, S., Gabelle, A., & Lehmann, S. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200780040 · Cited by 102 · see citing works

Analytical Pitfalls and Challenges in Clinical Metabolomics

Köhler, I., Verhoeven, A., Derks, R. J. E., & Giera, M. A. (2016) · Bioanalysis · doi:10.4155/bio-2016-0090 · Cited by 102 · see citing works

Blood‐based metabolic signatures in Alzheimer's disease

de Leeuw, F. A., Peeters, C. F. W., Kester, M. I., Harms, A. C., Struys, E. A., Hankemeier, T., van Vlijmen, H. W. T., van der Lee, S. J., van Duijn, C. M., Scheltens, P., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.006 · Cited by 102 · see citing works

Metabolomics studies in brain tissue: A review

González-Riaño, C., Garcı́a, A., & Barbas, C. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.07.008 · Cited by 101 · see citing works

Distinctive Pattern of Serum Elements During the Progression of Alzheimer’s Disease

Paglia, G., Miedico, O., Cristofano, A., Vitale, M., Angiolillo, A., Chiaravalle, A. E., Corso, G., & Costanzo, A. D. (2016) · Scientific Reports · doi:10.1038/srep22769 · Cited by 99 · see citing works

Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease

Taddei, K., Clarnette, R., Gandy, S., & Martins, R. N. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13394-8 · Cited by 98 · see citing works

Direct Infusion Mass Spectrometry for Metabolomic Phenotyping of Diseases

González‐Domínguez, R., Sayago, A., & Fernández‐Recamales, Á. (2016) · Bioanalysis · doi:10.4155/bio-2016-0202 · Cited by 98 · see citing works

A new metabolomic workflow for early detection of Alzheimer's disease

Ibáñez, C., Simó, C., Barupal, D. K., Fiehn, O., Kivipelto, M., Cedazo-Mı́nguez, Á., & Cifuentes, A. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2013.06.005 · Cited by 96 · see citing works

Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease

González‐Domínguez, R., García‐Barrera, T., Vitórica, J., & Gómez‐Ariza, J. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.09.014 · Cited by 96 · see citing works

Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry

González‐Domínguez, R., García‐Barrera, T., Vitórica, J., & Gómez‐Ariza, J. L. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.10.009 · Cited by 92 · see citing works

Measurement of Apolipoprotein E (apoE) in Cerebrospinal Fluid

Hesse, C., Larsson, H. E., Fredman, P., Minthon, L., Andreasen, N., Davidsson, P., & Blennow, K. (2000) · Neurochemical Research · doi:10.1023/a:1007516210548 · Cited by 89 · see citing works

A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease

Greenberg, N., Grassano, A., Thambisetty, M., Lovestone, S., & Legido‐Quigley, C. (2009) · Electrophoresis · doi:10.1002/elps.200800589 · Cited by 89 · see citing works

Quantitative and Wide-Ranging Profiling of Phospholipids in Human Plasma by Two-dimensional Liquid Chromatography/Mass Spectrometry

Sato, Y., Nakamura, T., Aoshima, K., & Oda, Y. (2010) · Analytical Chemistry · doi:10.1021/ac102211r · Cited by 86 · see citing works

Discovery and development of biomarkers of neurological disease

Dunckley, T. L., Coon, K. D., & Stephan, D. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03353-7 · Cited by 76 · see citing works

Suppression of adiponectin receptor 1 promotes memory dysfunction and Alzheimer’s disease-like pathologies

Kim, M. W., Abid, N. B., Jo, M. G., Jo, M. G., Yoon, G. H., & Kim, M. O. (2017) · Scientific Reports · doi:10.1038/s41598-017-12632-9 · Cited by 72 · see citing works

Targeted metabolomics and medication classification data from participants in the ADNI1 cohort

John‐Williams, L. S., Blach, C., Toledo, J. B., Rotroff, D. M., Kim, S., Klavins, K., Baillie, R., Han, X., MahmoudianDehkordi, S., Jack, J., et al. (2017) · Scientific Data · doi:10.1038/sdata.2017.140 · Cited by 72 · see citing works

Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease

Samakashvili, S., Ibáñez, C., Simó, C., Gil-Bea, F. J., Winblad, B. G., Cedazo-Mı́nguez, Á., & Cifuentes, A. (2011) · Electrophoresis · doi:10.1002/elps.201100139 · Cited by 69 · see citing works

Age-Associated Changes of Brain Copper, Iron, and Zinc in Alzheimer's Disease and Dementia with Lewy Bodies

Graham, S. F., Nasaruddin, M. L., Carey, M. P., Hölscher, C., McGuinness, B., Kehoe, P. G., Love, S., Passmore, P., Elliott, C. T., Meharg, A. A., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140684 · Cited by 63 · see citing works

Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy‐based metabolomics

Barba, I., Fernández-Montesinos, R., García‐Dorado, D., & Pozo, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00385.x · Cited by 63 · see citing works

Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD)

Wood, P. L., Locke, V. A., Herling, P., Passaro, A., Vigna, G. B., Volpato, S., Valacchi, G., Cervellati, C., & Zuliani, G. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.11.004 · Cited by 60 · see citing works

1H NMR Metabolomic Signatures in Five Brain Regions of the AβPPswe Tg2576 Mouse Model of Alzheimer's Disease at Four Ages

Lalande-Martin, J., Halley, H., Balayssac, S., Gilard, V., Dejean, S., Martino, R., Francès, B., Lassalle, J., & Malet‐Martino, M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130023 · Cited by 58 · see citing works

Metabonomic Profiling of TASTPM Transgenic Alzheimer’s Disease Mouse Model

Hu, Z., Browne, E. R., Liu, T., Angel, T. E., Ho, P. C., & Chan, E. C. Y. (2012) · Journal of Proteome Research · doi:10.1021/pr300666p · Cited by 58 · see citing works

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice

Chen, S., Cai, Q., Shen, Y., Wang, P., Teng, G., Zhang, W., & Zang, F. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.016 · Cited by 56 · see citing works

Development of Isotope Labeling Liquid Chromatography Mass Spectrometry for Mouse Urine Metabolomics: Quantitative Metabolomic Study of Transgenic Mice Related to Alzheimer’s Disease

Peng, J., Guo, K., Xia, J., Zhou, J., Yang, J., Westaway, D. A., Wishart, D. S., & Li, L. (2014) · Journal of Proteome Research · doi:10.1021/pr500828v · Cited by 53 · see citing works

Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer's disease

González‐Domínguez, R., García‐Barrera, T., Vitórica, J., & Gómez‐Ariza, J. L. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.01.025 · Cited by 53 · see citing works

Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: Beta-amyloid(1-42), tau, phospho-tau-181 and total protein

Marksteiner, J., Hinterhuber, H., & Hinterhuber, C. (2007) · Drugs of today · doi:10.1358/dot.2007.43.6.1067341 · Cited by 52 · see citing works

Increased CSF levels of nerve growth factor in patients with Alzheimer’s disease

Hock, C., Heese, K., Müller-Spahn, F., Huber, P., Riesen, W., Nitsch, R. M., & Otten, U. (2000) · Neurology · doi:10.1212/wnl.54.10.2009 · Cited by 52 · see citing works

Metabolomic-Driven Elucidation of Serum Disturbances Associated with Alzheimer';s Disease and Mild Cognitive Impairment

González‐Domínguez, R., Rupérez, F. J., García‐Barrera, T., Barbas, C., & Gómez‐Ariza, J. L. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160129095138 · Cited by 52 · see citing works

A novel approach for LC-MS/MS-based chiral metabolomics fingerprinting and chiral metabolomics extraction using a pair of enantiomers of chiral derivatization reagents

Takayama, T., Mochizuki, T., Todoroki, K., et al. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2015.10.010 · Cited by 51 · see citing works

NMR-based metabolomics of urine in a mouse model of Alzheimer’s disease: identification of oxidative stress biomarkers

Fukuhara, K., Ohno, A., Ota, Y., Senoo, Y., Maekawa, K., Okuda, H., Kurihara, M., Okuno, A., Niida, S., Saito, Y., et al. (2013) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.12-118 · Cited by 50 · see citing works

Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains

Hejazi, L., Wong, J. W. H., Cheng, D., Proschogo, N. W., Ebrahimi, D., Garner, B., & Don, A. S. (2011) · Biochemical Journal · doi:10.1042/bj20110566 · Cited by 49 · see citing works

Meta-Analysis of Peripheral Blood Apolipoprotein E Levels in Alzheimer’s Disease

Wang, C., Yu, J., Wang, H.-F., Jiang, T., Tan, C., Meng, X., Soares, H. D., & Tan, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089041 · Cited by 49 · see citing works

Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer’s disease in CRND8 mice

Lin, S., Liu, H., Kanawati, B., Liu, L., Dong, J., Li, M., Huang, J., Schmitt‐Kopplin, P., & Cai, Z. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6825-1 · Cited by 47 · see citing works

Drug Delivery to the Brain

Hammarlund‐Udenaes, M., Thorne, R. G., & de Lange, E. C. M. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7 · Cited by 42 · see citing works

Metabolomics and Personalized Medicine

Koen, N., du Preez, I., & Loots, D. T. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.09.003 · Cited by 42 · see citing works

A novel Alzheimer’s disease drug candidate targeting inflammation and fatty acid metabolism

Daugherty, D., Goldberg, J., Fischer, W. H., Dargusch, R., Maher, P. A., & Schubert, D. A. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0277-3 · Cited by 42 · see citing works

Quantification of 1H NMR spectra of human cerebrospinal fluid: a protocol based on constrained total-line-shape analysis

Jukarainen, N., Korhonen, S., Laakso, M. P., Korolainen, M. A., Niemitz, M., Soininen, P., Tuppurainen, K. A., Vepsäläinen, J., Pirttilä, T., & Laatikainen, R. (2008) · Metabolomics · doi:10.1007/s11306-008-0106-6 · Cited by 41 · see citing works

Recent advances in liquid‐phase separations for clinical metabolomics

Köhler, I., & Giera, M. A. (2016) · Journal of Separation Science · doi:10.1002/jssc.201600981 · Cited by 41 · see citing works

A multicenter, randomized, placebo‐controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol

Saitô, S., Kojima, S., Oishi, N., Kakuta, R., Maki, T., Yasuno, F., Nagatsuka, K., Yamamoto, H., Fukuyama, H., Fukushima, M., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.10.001 · Cited by 41 · see citing works

Cerebrospinal fluid metabolic profiles in multiple sclerosis and degenerative dementias obtained by high resolution proton magnetic resonance spectroscopy.

Nicoli, F., Vion‐Dury, J., Confort-Gouny, S., et al. (1996) · PubMed · Cited by 40 · see citing works

On the Advantages of Radially Elongated Structures in Microchip-Based Liquid Chromatography

Beeck, J. O. D., Callewaert, M., Ottevaere, H., et al. (2013) · Analytical Chemistry · doi:10.1021/ac400576s · Cited by 40 · see citing works

Ion mobility-mass spectrometry and orthogonal gas-phase techniques to study amyloid formation and inhibition

Hoffmann, W., von Helden, G., & Pagel, K. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.03.002 · Cited by 40 · see citing works

Alterations of the volatile metabolome in mouse models of Alzheimer’s disease

Kimball, B. A., Wilson, D. A., & Wesson, D. W. (2016) · Scientific Reports · doi:10.1038/srep19495 · Cited by 39 · see citing works

Alzheimer's Disease: Brain Desmosterol Levels

Wısnıewskı, T., Newman, K., & Javitt, N. B. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121453 · Cited by 33 · see citing works

Metal Ions in Alzheimer's Disease Brain

Sastre, M., Ritchie, C. W., & Hajji, N. (2015) · Cited by 33 · see citing works

Discovery and Confirmation of Diagnostic Serum Lipid Biomarkers for Alzheimer’s Disease Using Direct Infusion Mass Spectrometry

Anand, S., Barnes, J. M., Young, S. A., García, D. M., Tolley, H. D., Kauwe, J. S. K., & Graves, S. W. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170035 · Cited by 31 · see citing works

Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer's Disease in the Transgenic CRND8 Mice

Tang, Z., Liu, L., Li, Y., Dong, J., Li, M., Huang, J., Lin, S., & Cai, Z. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160129095340 · Cited by 28 · see citing works

Comparative Incidence of Conformational, Neurodegenerative Disorders

de Pedro‐Cuesta, J., Rábano, A., Martínez‐Martín, P., Ruiz-Tovar, M., Alcalde-Cabero, E., Almazán‐Isla, J., Avellanal, F., & Calero, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137342 · Cited by 24 · see citing works

Metabolomics of aging requires large-scale longitudinal studies with replication

Mäkinen, V., & Ala‐Korpela, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607062113 · Cited by 21 · see citing works

NMR metabolomic of frontal cortex extracts: First study comparing two neurodegenerative diseases, Alzheimer disease and amyotrophic lateral sclerosis

Botosoa, E. P., Zhu, M., Marbeuf‐Gueye, C., et al. (2012) · IRBM · doi:10.1016/j.irbm.2012.08.002 · Cited by 19 · see citing works

Metabolomics applied in bioenergy

Abdelnur, P. V., Caldana, C., & Martins, M. C. M. (2014) · Chemical and Biological Technologies in Agriculture · doi:10.1186/s40538-014-0022-0 · Cited by 17 · see citing works

Neurons and mechanisms of neuronal death in neurodegenerative diseases: a brief review.

Waggie, K. S., Kahle, P. J., & Tolwani, R. J. (1999) · PubMed · Cited by 17 · see citing works

Glycogen-synthase kinase-3β is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment

Marksteiner, J., & Humpel, C. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.02.007 · Cited by 16 · see citing works

Separations using a porous‐shell pillar array column on a capillary LC instrument

Malsche, W. D., Bruyne, S. D., Beeck, J. O. D., et al. (2012) · Journal of Separation Science · doi:10.1002/jssc.201200279 · Cited by 14 · see citing works

Metabolomics-based promising candidate biomarkers and pathways in Alzheimer's disease

Kang, J., Lü, J., & Zhang, X. (2015) · Die Pharmazie · doi:10.31083/ph.2015.4859 · Cited by 9 · see citing works

Metabolomics in the Study of Alzheimer's Disease

Ibáñez, C., Valdés, A., García‐Cañas, V., & Simó, C. (2014) · Comprehensive analytical chemistry · doi:10.1016/b978-0-444-62650-9.00010-5 · Cited by 4 · see citing works

Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery

Buccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021) · Antioxidants · doi:10.3390/antiox10091353 · Cited by 179 · see citing works

Effects of Aerobic Exercise Training on Systemic Biomarkers and Cognition in Late Middle-Aged Adults at Risk for Alzheimer’s Disease

Gaitán, J. M., Moon, H. Y., Stremlau, M., Dubal, D. B., Cook, D. B., Okonkwo, O. C., & van Praag, H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.660181 · Cited by 160 · see citing works

Targeted metabolomic analysis of nitric oxide/L-arginine pathway metabolites in dementia: Association with pathology, severity, and structural brain changes

Fleszar, M. G., Wiśniewski, J., Zboch, M., Diakowska, D., Gamian, A., & Krzystek-Korpacka, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50205-0 · Cited by 80 · see citing works

Mass spectrometry-based metabolomics in biomarker-assisted drug discovery and oxidative stress research

Sivaram, V., Kumar, A., & Devi, S. (2017) · Drug Development and Therapeutics · doi:10.4103/ddt.ddt_2_16

Metabolomics of diabetes and cardiovascular disease

Rahman, M., Qureshi, R., Bruginski, E., Alazmi, M., Soufan, O., Biswas, K. H., & Alam, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99924-3.00002-9 · Cited by 1 · see citing works

Power of metabolomics in biomarker discovery and mining mechanisms of obesity

Zhang, A., Sun, H., & Wang, X. (2012) · Obesity Reviews · doi:10.1111/obr.12011 · Cited by 123 · see citing works

Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential

Tuñón, J., Barbas, C., Blanco‐Colio, L. M., Burillo, E., Lorenzo, Ó., Martı́n-Ventura, J. L., Mas, S., Rupérez, F. J., & Egido, J. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1217775 · Cited by 19 · see citing works

Biomarkers for the Clinical Diagnosis of Alzheimer’s Disease: Metabolomics Analysis of Brain Tissue and Blood

Wang, Y., Sun, Y., Luo, Y., Peng, D., Li, X., Yang, B., Wang, Q., & Kuang, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700587 · Cited by 28 · see citing works